While not approved for menopause treatment, these medications may complement hormone therapy for women experiencing brain fog, metabolic syndrome, or midlife weight gain, as they target metabolic and neurologic pathways affected by declining estrogen
If any marker shifts outside normal range, discontinue use and consult a physician
Recent trials have shown: Up to 20% body weight reduction with weekly GLP-1 agonists (Wilding et al., NEJM) Improvements in HbA1c, fasting glucose, and cardiovascular outcomes (Marso et al., NEJM) This drug class is now widely used for: Obesity (with or without diabetes) Type 2 diabetes PCOS-related insulin resistance Metabolic syndrome Common Side Effects and Patient Concerns Despite their benefits, GLP-1 agonists are not without risks or drawbacks
How Compounded GLP-1 Medications Reduce Your Cost Compounded semaglutide and tirzepatide from licensed 503A pharmacies cost 7085% less than brand equivalents while delivering the same active pharmaceutical ingredient